# Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

> **NCT00517491** · PHASE2 · WITHDRAWN · sponsor: **Ipsen**

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00517491
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative reasons
- **Last updated:** 2019-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517491, "Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00517491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*